{
  "id": 3582,
  "text": "1569.Garcia, A.A., Blessing, J.A., Vaccarello, L.& Roman, L.D.Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.Am J Clin Oncol 30, 428-431 (2007).",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: 1569.Garcia, A.A., Blessing, J.A., Vaccarello, L.& Roman, L.D.Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.Am J Clin Oncol 30, 428-431 (2007).\n\n<question>: \n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n",
  "ChatGPT_response_0": "是的，紫杉醇类化疗药物，如多西他赛（docetaxel），确实曾被用于治疗对标准疗法无效的宫颈鳞状细胞癌的临床试验研究。例如，在一项针对难治性宫颈鳞状细胞癌的II期临床试验中，多西他赛被用作研究对象，旨在评估其在此类患者中的疗效和安全性。这表明紫杉醇类药物可能作为一种治疗选择在难治性宫颈鳞状细胞癌的患者中进行了探索性研究。",
  "query": "**在治疗对标准疗法无效的宫颈鳞状细胞癌时，紫杉醇类化疗药物是否被用于临床试验研究？**",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: **在治疗对标准疗法无效的宫颈鳞状细胞癌时，紫杉醇类化疗药物是否被用于临床试验研究？**\n\n<reference text>: 1569.Garcia, A.A., Blessing, J.A., Vaccarello, L.& Roman, L.D.Phase II clinical trial of docetaxel in refractory squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.Am J Clin Oncol 30, 428-431 (2007).\n\n**如果text中内容跟宫颈癌无关，请回复'SKIP'**\n\n<reply>: ",
  "response": "是的，紫杉醇类化疗药物，如多西他赛（docetaxel），确实曾被用于治疗对标准疗法无效的宫颈鳞状细胞癌的临床试验研究。例如，在一项针对难治性宫颈鳞状细胞癌的II期临床试验中，多西他赛被用作研究对象，旨在评估其在此类患者中的疗效和安全性。这表明紫杉醇类药物可能作为一种治疗选择在难治性宫颈鳞状细胞癌的患者中进行了探索性研究。"
}